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Minimally invasive procedures such as endovascular aneurysm repair 
(EVAR), transcatheter aortic valve implantation (TAVI) and implantation 
of mechanical circulatory support (MCS) are gaining ground on 
traditional surgery.1–3 These procedures require large-bore access, which 
is inherently associated with vascular complications and bleeding. 
Despite the reduction in size of these devices (Table 1), vascular- and 
bleeding complications are frequent and are reported as high as 20% 
in TAVI and 12–22% in EVAR.4–7 These adverse events lead to prolonged 
hospitalisation, the need for packed cell transfusion and an increased 
short and longer-term mortality.8 Common risk factors for access site 
complications are female sex, extremes of weight, renal insufficiency 
and anticoagulation use.9–10 This article focuses on strategies for femoral 
access and closure when using large-bore devices.
Obtaining Access
Good closure starts with good access. The ideal puncture site is 
located in the common femoral artery between the inferior border 
of the inferior epigastric artery (IEA) that marks the retroperitoneal 
space and above the femoral bifurcation. Punctures that are too 
high are non-compressible and are associated with retroperitoneal 
bleeding.11 Punctures below the femoral bifurcation, in a small calibre 
artery, are unsuitable for large-sized sheaths used in EVAR, TAVI and 
mechanical LV support and should not be closed with percutaneous 
closure devices per respective instructions for use. There are different 
strategies for obtaining peripheral access for large-bore devices.
Anatomical Landmarks
When using anatomical landmarks, the operator identifies the inguinal 
ligament by connecting the anterior-superior iliac spine with the 
symphysis pubis. Under palpation of the femoral pulse, the needle is 
inserted into the common femoral artery just below the imaginary line 
of the inguinal ligament. This strategy is highly dependent on operator 
experience, which is dropping with increasing numbers of procedures 
performed via the radial artery – the so-called radial paradox.12,13 
A retrospective study by Pitta et al. found that in approximately 13% 
of the cases, the actual access site was located outside the optimal 
location, when solely anatomical landmarks were used for puncture 
guidance. Access outside the target location was associated with more 
vascular complications.14 
Ultrasound-guided Access
Ultrasound-guided access is performed using a linear ultrasound 
probe. The first step is to visualise the common femoral artery 
bifurcation in a longitudinal view to determine the exact bifurcation 
location and extent of arterial wall calcifications. The probe is then 
turned counter-clockwise to get a cross-sectional view of the femoral 
artery above the bifurcation. Vein and artery are distinguished by 
means of compression. The femoral artery is punctured under a 45° 
angle, the correct needle pathway and vessel entry is confirmed by 
ultrasound (Figure 1).
Ultrasound-guided access precludes radiation and is easy to apply 
after a steep learning curve. It provides a real-time image of the 
puncture site of interest. Ultrasound allows:
• the differentiation of non-compressible and pulsatile arteries from 
compressible veins; 
• the identification of the femoral bifurcation; 
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• the appreciation of the degree, location and distribution of 
calcifications and the selection of a puncture site without anterior 
wall calcification; 
• the monitoring of needle entry into the vessel, avoiding side or 
posterior wall puncture.15 
Compared with fluoroscopic guidance, ultrasound guidance reduces 
the number of attempts and median time to access.16 
Fluoroscopic-guided Access
Fluoroscopic-guided access assumes a consistent spatial relationship 
between the common femoral artery and femoral head.17 Under X-ray, 
a radiopaque instrument, such as a haemostat or puncture needle, 
is placed over the femoral head to locate the appropriate height 
for puncture. Assumptions may be inaccurate in patients with high 
femoral bifurcations. Alternatively, a wire or (e.g. pigtail) catheter can be 
inserted from a contralateral access and navigated towards the level 
of the ipsilateral femoral head to serve as a target for the fluoroscopy-
guided puncture. A small contrast injection through the pigtail catheter 
may further map the common femoral artery and serve as a bull’s eye 
for the operator. Fluoroscopy-guided arterial puncture is effective and 
associated with a low incidence of vascular complications, but it has 
not been shown to be superior to the use of anatomical landmarks.18–20 
The major downside of this technique is its reliance on radiation, in 
particular to the operator’s hands.
Surgical Cut-down
Surgical cut-down can expose the common femoral artery and allows 
for direct-vision access and allows for direct-suture closure. Surgical 
cut-down is associated with a longer procedure time, increased length 
of hospitalisation and more wound infections.21–23 Complications seem 




In principle, a surgical suture technique is applied for closure after 
surgical cut-down for femoral access. Surgical cut-down and closure 
increases the chance for wound infection or iatrogeneous femoral 
nerve damage. At present, most TAVI and EVAR procedures are 
performed in a total percutaneous matter, but a surgical cut-down may 
still be preferred in selected patients, such as the very obese or those 
with femoral grafts or stents.25 
Suture-based Closure Devices
The vast majority of large-bore vessel closure is performed by 
percutaneous suture- based techniques like the Prostar® XL and 
multiple ProGlide® (Abbott Vascular) vascular closure devices (VCD) 
(Figure 2). Both devices are predominantly inserted using a pre-
closure technique.
Table 1: Different Large-bore Devices and Their 
Sheath Sizes
Large-bore Devices Sheath Size
TAVI Devices 14–19 Fr
Acurate Neo 18 Fr, 19 Fr
Evolut PRO 16 Fr
Evolut R 14 Fr
Lotus Edge 14 Fr, 15 Fr
Portico 18 Fr, 19 Fr
Sapien 3 14 Fr, 16 Fr
EVAR 18–24 Fr
Mechanical Support
Impella 2.5 13–14 Fr
Impella CP 14 Fr
Impella 5.0 21 Fr
Pulsecath 2L 17 Fr
Pulsecath 3L 21 Fr
EVAR = endovascular aneurysm repair; TAVI = transcatheter aortic valve implantation.
Figure 1: Ultrasound-guided Access
A: Common femoral artery and femoral vein (semi-compressed). Dashed line: Needle 
pathway. B: Calcification of the posterior arterial wall marked in red. CFA = common femoral 
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The Prostar XL device is inserted over a guidewire. Its position in the 
artery is confirmed when pulsatile flow evades the main tube of the 
device. Four pre-prepared sutures inside the device are pulled out 
while maintaining the device in the same position. This allows four 
needles to be pulled back, leaving the sutures in place. The arteriotomy 
can be closed by pulling the sutures and closing the knots. 
The ProGlide technique typically requires two devices for large-bore 
arteriotomies. The devices are inserted before the procedure and are 
deployed at the 10 o’clock and 2 o’clock position. After the procedure 
is concluded, the introducer sheath is removed. The sutures are 
approximated and the vessel wall is closed.26 Both suture-based 
techniques can be executed with a safety wire in place in order to use 
additional suture- or plug-based closure devices if there is incomplete 
arteriotomy closure. 
ProGlide was originally introduced to clinical practice for small-bore 
arteriotomy closure, but its use was extended to EVAR, first under 
surgical cut-down and later in a completely percutaneous fashion.27 
Compared to surgical cut-down, there are fewer groin complications 
when using a VCD, and the procedural time is shorter (91 minutes ± 32 
versus 153 minutes ± 112; p<0.05).28,29
Figure 2: Commercially Available Vascular Closure Devices
Prostar® XL ProGlide® PerQseal® InSeal
Suture-based Suture-based Collagen-based
8.5–10 Fr 5–8 Fr 10–14 Fr (14 Fr system) 14–21 Fr
14–22 Fr (18 Fr system)(off-label use > 10 Fr) (off-label use > 8 Fr)




Source: Abbott Vascular, Essential Medical, InSeal Medical and Vivasure Medical.
Figure 3: Forest Plot Showing Odds Ratio for Any Bleeding and Any Vascular Complication
Study Events EventsTotal WeightTotal
Suture-based VCD
Any bleeding (VARC-2)
Any vascular complication (VARC-2)
OR
MH, xed, 95% CI
OR
MH, Fixed, 95% CI
MANTA™
Total (95% CI) 307 483 100.0% 0.79 [0.55, 1.13]
Biancari et al. 2018 27 107 26 115 1.16 [0.62, 2.14]
0.2 0.5
Favours MANTA Favours suture-based VCD
1 2 5
27.8%
14 89 43 257 0.93 [0.48, 1.79]27.7%
21 111 37 111 0.47 [0.25, 0.87]44.5%
de Palma et al. 2018
Moriyama et al. 2018
Total events
Heterogeneity: chi2=4.48, d.f.=2 (p=0.11); I2=55%
Test for overall effect: Z=1.31 (p=0.19)
62 106
Study Events EventsTotal WeightTotal
Suture-based VCD OR
MH, xed, 95% CI
OR
MH, Fixed, 95% CI
MANTA
Total (95% CI) 307 483 100.0% 0.89 [0.56, 1.42]
Biancari et al. 2018 14 107 17 115 0.87 [0.40, 1.86]
0.2 0.5
Favours MANTA Favours suture-based VCD
1 2 5
37.7%
6 89 8 257 2.25 [0.76, 6.67]10.2%
16 111 23 111 0.64 [0.32, 1.30]52.1%
de Palma et al. 2018
Moriyama et al. 2018
Total events
Heterogeneity: chi2=3.61, d.f.=2 (p=0.16); I2=45%
Test for overall effect: Z=0.48 (p=0.63)
36 48
*Biancari et al. comprises only data on major and life threatening bleeding, minor bleeding data not available. MH = Mantel-Haenszel test; VARC-2 = Valve Academic Research Consortium-2; 
VCD = vascular closure device.
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A propensity matched analysis in TAVI patients by Barbash et al. 
showed lower rates of major vascular complications with use 
of ProGlide compared to Prostar XL (1.9% versus 7.4%; p<0.001) 
and lower rates of major (3.2% versus 16.7%; p<0.001) and minor 
bleedings (8.9% versus 13.6%; p=0.032).7 Conversely, a study in an 
Italian hospital reported more vascular complications with ProGlide 
versus Prostar XL closure (24.0% versus 11.4%; p=0.007).30 Basically, 
local experience will determine suture-based closure success and it 
is recommended that each operator or centre adopts and masters 
one suture-based technique.
Suture-based closure has also been successfully applied for closure of 
axillary and subclavian arteriotomies.31,32 
Collagen-based Closure
The MANTA™ VCD (Essential Medical) is a collagen-based closure 
device (Figure 2). It consists of a poly-lactic coglycolic toggle within the 
artery, connected to a bovine collagen plug, exterior to the vessel wall. 
A stainless-steel lock is tampered down pushing the collagen and 
toggle together in order to sandwich the arterial puncture site between 
the toggle and the collagen. The proper amount of tension that the 
operator has to apply is indicated by the appearance of a green 
marker on the device handle. The toggle and collagen plug resolve 
completely in 6 months.33 The MANTA has a 14 Fr and 18 Fr version 
for arteriotomy closure between 10 and 14 Fr and 14 and 22 Fr, 
respectively, and obtained the CE mark in 2016. The MANTA has 
also been applied for completely percutaneous closure of axillary 
arteriotomies after TAVI.34,35
There are no randomised head-to-head comparisons, but retrospective 
data show lower bleeding complications and comparable vascular 
complications with the MANTA device compared to the Prostar 
XL (Major bleeding 2.3% versus 9.3%; p=0.03; major vascular 2.3% 
versus 0.4%; p=0.48).36 A propensity matched analysis by Moriyama 
et al. confirmed less VARC-2 bleeding (18% versus 33%; p=0.01) 
but no difference in vascular complications (14% versus 21%; 
p=0.21) with MANTA.37 Biancari et al. found no significant difference 
between the MANTA and ProGlide in terms of bleeding (22% versus 
25%; p=0.469) or major vascular complications (12% versus 9%; 
p=0.498)38 (Figure 3).
The MANTA device has a short mean time to haemostasis, ranging 
from 22 seconds to 2 minutes 23 seconds. There is no comparable time 
to haemostasis data for other VCDs.35,36,39 
Miscellaneous
Other novel dedicated large-bore closure devices include the InSeal 
(InSeal Medical) and PerQseal® (Vivasure Medical) VCD (Table 2).
The InSeal VCD is a membrane-based device consisting of a self-
expanding nitinol frame, a biodegradable membrane and a bioresorbable 
polyglycolic acid (PGA) tether. The InSeal device is introduced with the 
membrane in a collapsed configuration. The sheath is then pulled back 
and the release wire is pulled to deploy the VCD. The membrane is 
pushed against the arteriotomy site by the nitinol frame and traction 
is kept by keeping the tether fixed to the skin using a steristrip or 
suture. The flexible membrane should compensate for arterial wall 
irregularities and calcifications. The specially designed frame allows 
re-access within 26 weeks. The first in human experience showed 
technical and therapeutic success in all nine cases.40 Unpublished 
post CE mark clinical experience showed a mean time to haemostasis 
<1 minute and 0% Major VARC-2 vascular complications and 7.7% 
bleeding complications in a series of 52 patients.41 
The PerQseal VCD consists of a flexible intravascular patch supported 
by a scaffold. The surface of the patch is textured to promote 
adherence to the vessel wall. An external locator extends through 
the arteriotomy, which keeps the patch in place. The implant is fully 
absorbable after 180 days. It received the CE mark in 2016. In 120 
patients, from the unpublished Frontier series of studies, including 
TAVI, EVAR and thoracic endovascular aortic repair, no major vascular 
complications occurred.42
Conclusion
The use of large-bore arteriotomies is peaking with the expanding 
market of structural heart interventions and MCS. Indeed, catheter-
based techniques, such as EVAR and TAVI have greatly replaced 
conventional surgical operations. Optimal access site management, 
including the proper puncture and arteriotomy closure technique, is 
pivotal to secure procedural safety and will ultimately determine the 
success of catheter-based therapies in clinical practice. 
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